Concepedia

Manuel Ayala

MA

Statistics

Publications

3

Citations

1.6K

H-Index

3

Active since

2010

Affiliations

Mexican Social Security Institute(Current)

Hospital de Especialidades

The University of Texas MD Anderson Cancer Center

University of Bologna

Jena University Hospital

Manuel Ayala is an author at Mexican Social Security Institute specializing in hematologic malignancy therapy, pharmacology, and chronic myeloid leukemia therapy.

ORCID

Publications per year

2010–2016

3

Publications

3

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Hagop M. Kantarjian, Neil P. Shah, Andreas Hochhaus et al. · New England Journal of Medicine · 2010 · 1.6K citations

, , +10

Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial

Jörge E. Cortes, Cármino Antônio De Souza, Manuel Ayala et al. · The Lancet Haematology · 2016 · 40 citations · Full text

, , +9

Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study.

Hagop M. Kantarjian, Neha Shah, Andreas Hochhaus et al. · Journal of Clinical Oncology · 2010 · 16 citations

, , +10

1–3 of 3